GC3114

BIOLOGICAL2 trials

Sponsors

Green Cross Corporation

Conditions

Influenza, Human

Phase 1

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

CompletedNCT03357263

Green Cross CorporationInfluenza, Human

Start: 2017-11-20End: 2017-12-22Updated: 2018-11-19

Phase 2

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects

CompletedNCT03657719

Green Cross CorporationInfluenza, Human

Start: 2018-10-01End: 2018-12-13Updated: 2019-01-04

Related Papers

Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.

2019-07-312 citations